APA (7th ed.) Citation

Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Serra, F., . . . Cassaniti, I. (2022). Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: A longitudinal cohort study with a focus on the variants of concern. ESMO open, 7(5), 100574. https://doi.org/10.1016/j.esmoop.2022.100574

Chicago Style (17th ed.) Citation

Lasagna, A., et al. "Six-month Humoral and Cellular Immune Response to the Third Dose of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients with Solid Tumors: A Longitudinal Cohort Study with a Focus on the Variants of Concern." ESMO Open 7, no. 5 (2022): 100574. https://doi.org/10.1016/j.esmoop.2022.100574.

MLA (9th ed.) Citation

Lasagna, A., et al. "Six-month Humoral and Cellular Immune Response to the Third Dose of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients with Solid Tumors: A Longitudinal Cohort Study with a Focus on the Variants of Concern." ESMO Open, vol. 7, no. 5, 2022, p. 100574, https://doi.org/10.1016/j.esmoop.2022.100574.